PTC Therapeutics (PTCT)
NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Forecast & Price Target

271 Followers
See the Price Targets and Ratings of:

PTCT Analyst Ratings

Moderate Buy
7Ratings
2 Buy
5 Hold
0 Sell
Based on 7 analysts giving stock ratings to
PTC
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PTCT Stock 12 Months Forecast

Average Price Target

$48.71
▲(22.76% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $48.71 with a high forecast of $62.00 and a low forecast of $40.00. The average price target represents a 22.76% change from the last price of $39.68.
Highest Price Target$62.00Average Price Target$48.71Lowest Price Target$40.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Upgrade Banner
Cantor Fitzgerald
$63.00
Buy
58.77%
Upside
Reiterated
Cantor says PTC should be up 30% today on Translarna study updateCantor says PTC should be up 30% today on Translarna study update
Cowen & Co.
$45.00
Hold
13.41%
Upside
Reiterated
PTC Therapeutics (PTCT) PT Lowered to $45 at CowenCowen analyst Joseph Thome lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $48.00) while maintaining a Market Perform rating after the company announced results of Translarnas Study 041 this morning.
Truist Financial
$60.00
Buy
51.21%
Upside
Reiterated
Truist Securities reiterates Buy Rating, $60 Price Target on PTC Therapeutics (PTCT)Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $60.00 price target on PTC Therapeutics (NASDAQ: PTCT), following the companys Q1 Update.
Bank of America Securities
$33.00
Sell
-16.83%
Downside
Reiterated
PTC Therapeutics (PTCT) PT Lowered to $33 at BofA SecuritiesBofA Securities analyst Tazeen Ahmad lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $33.00 (from $34.00) while maintaining a Underperform rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

PTCT Financial Forecast

PTCT Earnings Forecast
Next quarter’s earnings estimate for PTCT is -$1.41 with a range of -$1.88 to $0.28. The previous quarter’s EPS was -$1.53. PTCT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.44% of the time in the same period. In the last calendar year PTCT has Underperformed its overall industry.
Next quarter’s earnings estimate for PTCT is -$1.41 with a range of -$1.88 to $0.28. The previous quarter’s EPS was -$1.53. PTCT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 52.44% of the time in the same period. In the last calendar year PTCT has Underperformed its overall industry.
PTCT Sales Forecast
Next quarter’s sales forecast for PTCT is $198.61M with a range of $180.07M to $216.90M. The previous quarter’s sales results were $217.13M. PTCT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 42.84% of the time in the same period. In the last calendar year PTCT has Outperformed its overall industry.
Next quarter’s sales forecast for PTCT is $198.61M with a range of $180.07M to $216.90M. The previous quarter’s sales results were $217.13M. PTCT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 42.84% of the time in the same period. In the last calendar year PTCT has Outperformed its overall industry.
PTCT Analyst Recommendation Trends
In the current month, PTCT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PTCT average analyst price target in the past 3 months is $48.71
In the current month, PTCT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PTCT average analyst price target in the past 3 months is $48.71

PTCT Stock Forecast FAQ

What is PTCT’s average 12-month price target, according to analysts?
Based on analyst ratings, PTC Therapeutics’s 12-month average price target is $48.71.
    What is PTCT’s upside potential, based on the analysts’ average price target?
    PTC Therapeutics has 22.76% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PTCT a Buy, Sell or Hold?
          PTC Therapeutics has a conensus rating of Moderate Buy which is based on 2 buy ratings, 5 hold ratings and 0 sell ratings.
            What is PTC Therapeutics’s price target?
            The average price target for PTC Therapeutics is $48.71. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $62.00 ,the lowest forecast is $40.00. The average price target represents 22.76% Increase from the current price of $39.68.
              What do analysts say about PTC Therapeutics?
              PTC Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis